Sanofi to explore acquisition of cancer drugmaker Mirati- Bloomberg News (updated)

Mirati Therapeutics

05/10/2023 20:08

(Adds details and background throughout, shares in paragraph 3)
       Oct 5 (Reuters) - Paris-based drugmaker Sanofi  SASY.PA 
is exploring a potential acquisition of cancer drugmaker Mirati
Therapeutics  MRTX.O , Bloomberg News reported on Thursday
citing people familiar with the matter.
    Deliberations are ongoing and there is no certainty they
will result in an agreement, the report said, adding that Mirati
could also attract interest from other suitors.
    A Sanofi spokesperson responded to a Reuters' request saying
the company does not comment on market rumors. Mirati, whose
shares rose 25.48% to $53.83, did not immediately respond to
Reuters' request for a comment.
    Mirati's lung cancer drug, Krazati, had received the U.S.
health regulator's nod in December to treat adults with advanced
lung cancer.   
    
    


 (Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi
Majumdar)
 ((Sriparna.Roy@thomsonreuters.com;))